Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical Reviews in Allergy & Immunology
Erschienen in: Clinical Reviews in Allergy & Immunology 2/2016

17.08.2014

Biological Modulators in Eosinophilic Diseases

verfasst von: Panida Sriaroon, Mark Ballow

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Eosinophils can regulate local and systemic inflammation, and their presence in higher numbers appears to play an important role in the pathology of various atopic and inflammatory diseases. Eosinophil maturation, recruitment, and survival depend on several cytokine regulators, including interleukin (IL)-5, IL-4, and IL-13 as well as growth factors such as GM-CSF. Over the last decade, the approach to treating eosinophilic diseases has changed greatly. A number of biologic modulators have been developed to target eosinophilic inflammatory pathways, and their usage has resulted in variable clinical improvement in the treatment of eosinophilic-associated conditions. Novel targeted therapies that are safe and effective for treating these disorders are being investigated. This review summarizes the clinical use of biologic agents that have been studied in clinical trials or approved for treating eosinophilic diseases.
Literatur
1.
Rothenberg ME, Pomerantz JL, Owen WF Jr, Avraham S, Soberman RJ, Austen KF et al (1988) Characterization of a human eosinophil proteoglycan, and augmentation of its biosynthesis and size by interleukin 3, interleukin 5, and granulocyte/macrophage colony stimulating factor. J Biol Chem 263(27):13901–13908PubMed
2.
Sanderson CJ (1992) Interleukin-5, eosinophils, and disease. Blood 79(12):3101–3109PubMed
3.
Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P et al (2008) Eosinophils: biological properties and role in health and disease. Clin Exp Allergy J Br Soc Allergy Clin Immunol 38(5):709–750CrossRef
4.
Fulkerson PC, Rothenberg ME (2013) Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov 12(2):117–129PubMedCrossRef
5.
Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S et al (2005) The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 60(3):302–308PubMedCrossRef
6.
Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD et al (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108(2):184–190PubMedCrossRef
7.
Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J et al (2011) Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 154(9):573–582PubMedCrossRef
8.
Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF et al (2004) Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy J Br Soc Allergy Clin Immunol 34(4):632–638CrossRef
9.
Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J et al (2005) Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60(3):309–316PubMedCrossRef
10.
Soler M, Matz J, Townley R, Buhl R, O’Brien J, Fox H et al (2001) The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18(2):254–261PubMedCrossRef
11.
Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C (2005) The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 115(3):459–465PubMedCrossRef
12.
Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A et al (2009) Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360(10):973–984PubMedPubMedCentralCrossRef
13.
Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E et al (2009) Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 360(10):985–993PubMedCrossRef
14.
Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON et al (2012) Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380(9842):651–659PubMedCrossRef
15.
Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L et al (2007) A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 176(11):1062–1071PubMedCrossRef
16.
Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J et al (2011) Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 184(10):1125–1132PubMedCrossRef
17.
Kips JC, O’Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS et al (2003) Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 167(12):1655–1659PubMedCrossRef
18.
Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R et al (2013) Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 132(5):1086 e5–1096 e5PubMedCrossRef
19.
Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M (2007) Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370(9596):1422–1431PubMedCrossRef
20.
Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J et al (2010) A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 181(8):788–796PubMedCrossRef
21.
Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F et al (2013) Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368(26):2455–2466PubMedCrossRef
22.
Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR et al (2011) Lebrikizumab treatment in adults with asthma. N Engl J Med 365(12):1088–1098PubMedCrossRef
23.
Noonan M, Korenblat P, Mosesova S, Scheerens H, Arron JR, Zheng Y et al (2013) Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol 132(3):567 e12–574 e12PubMedCrossRef
24.
Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K et al (2013) A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 41(2):330–338PubMedPubMedCentralCrossRef
25.
Gauvreau GM, Boulet LP, Cockcroft DW, Fitzgerald JM, Carlsten C, Davis BE et al (2011) Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 183(8):1007–1014PubMedCrossRef
26.
De Boever EH, Ashman C, Cahn AP, Locantore NW, Overend P, Pouliquen IJ et al (2014) Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol 133(4):989–996PubMedCrossRef
27.
Gauvreau GM, Boulet LP, Cockcroft DW, Baatjes A, Cote J, Deschesnes F et al (2008) Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med 177(9):952–958PubMedCrossRef
28.
Neighbour H, Boulet LP, Lemiere C, Sehmi R, Leigh R, Sousa AR et al (2014) Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial. Clin Exp Allergy J Br Soc Allergy Clin Immunol 44(4):508–516CrossRef
29.
Pettipher R, Hunter MG, Perkins CM, Collins LP, Lewis T, Baillet M et al. (2014) Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. Allergy
30.
Busse WW, Wenzel SE, Meltzer EO, Kerwin EM, Liu MC, Zhang N et al (2013) Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. J Allergy Clin Immunol 131(2):339–345PubMedCrossRef
31.
Beeh KM, Kanniess F, Wagner F, Schilder C, Naudts I, Hammann-Haenni A et al (2013) The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol 131(3):866–874PubMedCrossRef
32.
Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348(13):1201–1214PubMedCrossRef
33.
Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J et al (2003) Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 101(12):4660–4666PubMedCrossRef
34.
Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU et al (2008) Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 358(12):1215–1228PubMedCrossRef
35.
Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ et al (2013) Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol 131(2):461 e1-5–467 e1-5CrossRef
36.
Klion AD, Law MA, Noel P, Kim YJ, Haverty TP, Nutman TB (2004) Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 103(8):2939–2941PubMedCrossRef
37.
Strati P, Cortes J, Faderl S, Kantarjian H, Verstovsek S (2013) Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody. Clin Lymphoma Myeloma Leuk 13(3):287–291PubMedPubMedCentralCrossRef
38.
Kim S, Marigowda G, Oren E, Israel E, Wechsler ME (2010) Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 125(6):1336–1343PubMedCrossRef
39.
Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B (2011) Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 155(5):341–343PubMedCrossRef
40.
Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W et al (2013) Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 131(1):110 e1–116 e1PubMedCrossRef
41.
Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F et al (2011) Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol 128(5):989 e1-8–995 e1-8CrossRef
42.
Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T et al (2006) Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 118(5):1133–1141PubMedCrossRef
43.
Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C et al (2010) Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 59(1):21–30PubMedCrossRef
44.
Otani IM, Anilkumar AA, Newbury RO, Bhagat M, Beppu LY, Dohil R et al (2013) Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis. J Allergy Clin Immunol 131(6):1576–1582PubMedPubMedCentralCrossRef
45.
Assa’ad AH, Gupta SK, Collins MH, Thomson M, Heath AT, Smith DA et al (2011) An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 141(5):1593–1604PubMedCrossRef
46.
Spergel JM, Rothenberg ME, Collins MH, Furuta GT, Markowitz JE, Fuchs G 3rd et al (2012) Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 129(2):456–463, 63 e1-3PubMedCrossRef
47.
McGrath KW, Icitovic N, Boushey HA, Lazarus SC, Sutherland ER, Chinchilli VM et al (2012) A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 185(6):612–619PubMedPubMedCentralCrossRef
48.
Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I et al (1990) Eosinophilic inflammation in asthma. N Engl J Med 323(15):1033–1039PubMedCrossRef
49.
Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P et al (2002) Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360(9347):1715–1721PubMedCrossRef
50.
Jayaram L, Pizzichini MM, Cook RJ, Boulet LP, Lemiere C, Pizzichini E et al (2006) Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 27(3):483–494PubMedCrossRef
51.
Holgate ST (2003) The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 22(3):470–477CrossRef
52.
Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA et al (2004) Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 170(8):836–844PubMedCrossRef
53.
Chapman KR, Boulet LP, Rea RM, Franssen E (2008) Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J 31(2):320–325PubMedCrossRef
54.
Bousquet J, Mantzouranis E, Cruz AA, Ait-Khaled N, Baena-Cagnani CE, Bleecker ER et al (2010) Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 126(5):926–938PubMedCrossRef
55.
Lotvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A et al (2011) Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 127(2):355–360PubMedCrossRef
56.
Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF et al (2004) Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 170(6):583–593PubMedCrossRef
57.
van Rensen EL, Evertse CE, van Schadewijk WA, van Wijngaarden S, Ayre G, Mauad T et al (2009) Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy 64(1):72–80PubMedCrossRef
58.
Holgate S, Smith N, Massanari M, Jimenez P (2009) Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy 64(12):1728–1736PubMedCrossRef
59.
Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR et al (1997) Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 100(1):110–121PubMedCrossRef
60.
MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J et al (1997) Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 158(3):1438–1445PubMed
61.
Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB (2003) Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 112(6):1147–1154PubMedCrossRef
62.
Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT (2011) Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol 127(6):1622–1624PubMedPubMedCentralCrossRef
63.
Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT (2013) A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol 132(6):1368–1374PubMedPubMedCentralCrossRef
64.
Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG et al (2006) Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 117(1):134–140PubMedCrossRef
65.
Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR et al (2007) Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol 120(3):688–695PubMedCrossRef
66.
Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C et al (2009) Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy J Br Soc Allergy Clin Immunol 39(2):271–279CrossRef
67.
Massanari M, Nelson H, Casale T, Busse W, Kianifard F, Geba GP et al (2010) Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 125(2):383–389PubMedCrossRef
68.
Galera C, Soohun N, Zankar N, Caimmi S, Gallen C, Demoly P (2009) Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol 19(3):225–229PubMed
69.
Vashisht P, Casale T (2013) Omalizumab for treatment of allergic rhinitis. Expert Opin Biol Ther 13(6):933–945PubMedCrossRef
70.
Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT et al (2013) Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol 162(1):89–93PubMedPubMedCentralCrossRef
71.
Jat KR, Walia DK, Khairwa A (2013) Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev 9, CD010288PubMed
72.
Tanou K, Zintzaras E, Kaditis AG (2014) Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence. Pediatr Pulmonol 49(5):503–507PubMedCrossRef
73.
Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF et al (2013) Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 187(8):804–811PubMedCrossRef
74.
Huang YC, Leyko B, Frieri M (2005) Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol 95(5):443–451CrossRef
75.
Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Bodzenta-Lukaszyk A (2010) Anti-IgE therapy with omalizumab decreases endothelin-1 in exhaled breath condensate of patients with severe persistent allergic asthma. Respir Int Rev Thorac Dis 80(6):534–542
76.
Pelaia G, Vatrella A, Maselli R (2012) The potential of biologics for the treatment of asthma. Nat Rev Drug Discov 11(12):958–972PubMedCrossRef
77.
Korn S, Haasler I, Fliedner F, Becher G, Strohner P, Staatz A et al (2012) Monitoring free serum IgE in severe asthma patients treated with omalizumab. Respir Med 106(11):1494–1500PubMedCrossRef
78.
Massanari M, Holgate ST, Busse WW, Jimenez P, Kianifard F, Zeldin R (2010) Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir Med 104(2):188–196PubMedCrossRef
79.
Barnes PJ (2012) Severe asthma: advances in current management and future therapy. J Allergy Clin Immunol 129(1):48–59PubMedCrossRef
80.
Bousquet J, Siergiejko Z, Swiebocka E, Humbert M, Rabe KF, Smith N et al (2011) Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy 66(5):671–678PubMedCrossRef
81.
Dal Negro RW, Tognella S, Pradelli L (2012) A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy. J Asthma Off J Assoc Care Asthma 49(8):843–848CrossRef
82.
Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P (2009) Safety and tolerability of omalizumab. Clin Exp Allergy J Br Soc Allergy Clin Immunol 39(6):788–797CrossRef
83.
Rodrigo GJ, Neffen H, Castro-Rodriguez JA (2011) Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 139(1):28–35PubMedCrossRef
84.
Milgrom H, Fowler-Taylor A, Vidaurre CF, Jayawardene S (2011) Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Curr Med Res Opin 27(1):163–169PubMedCrossRef
85.
Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J (2013) The eXpeRience registry: the ‘real-world’ effectiveness of omalizumab in allergic asthma. Respir Med 107(8):1141–1151PubMedCrossRef
86.
Cox L, Platts-Mills TA, Finegold I, Schwartz LB, Simons FE, Wallace DV et al (2007) American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 120(6):1373–1377PubMedCrossRef
87.
Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A et al (2006) Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 117(2):391–397PubMedCrossRef
88.
Cox L, Lieberman P, Wallace D, Simons FE, Finegold I, Platts-Mills T et al (2011) American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report. J Allergy Clin Immunol 128(1):210–212PubMedCrossRef
89.
Fernandez C, Busse W, Reisner C, Gupta N (2005) Clinical data do not suggest a causal relationship between omalizumab therapy and cancer. Proc Am Thorac Soc 2:A359
90.
Busse W, Buhl R, Fernandez Vidaurre C, Blogg M, Zhu J, Eisner MD et al (2012) Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol 129(4):983 e6–989 e6PubMedCrossRef
91.
Long A, Rahmaoui A, Rothman KJ, Guinan E, Eisner M, Bradley MS et al. (2014) Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol (in press)
92.
Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF (2009) Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 124(6):1210–1216PubMedCrossRef
93.
Baena-Cagnani CE, Gomez RM (2014) Current status of therapy with omalizumab in children. Curr Opin Allergy Clin Immunol 14(2):149–154PubMedCrossRef
94.
Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K et al (2012) Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11 years: a NICE single technology appraisal. PharmacoEconomics 30(11):991–1004PubMedCrossRef
95.
96.
Leckie MJ, ten Brinke A, Khan J, Diamant Z, O’Connor BJ, Walls CM et al (2000) Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356(9248):2144–2148PubMedCrossRef
97.
Plotz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S et al (2003) Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 349(24):2334–2339PubMedCrossRef
98.
Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE, Freese DK et al (2004) Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 113(1):115–119PubMedCrossRef
99.
Wenzel SE (2009) Eosinophils in asthma—closing the loop or opening the door? N Engl J Med 360(10):1026–1028PubMedCrossRef
100.
Hashimoto S, Bel EH (2012) Targeting IL-5 in severe asthma: a DREAM come true? Lancet 380(9842):626–627PubMedCrossRef
101.
Gleich GJ (2009) Anti-interleukin-5 therapy and severe asthma. N Engl J Med 360(24):2577, author reply 8PubMed
102.
Stein ML, Villanueva JM, Buckmeier BK, Yamada Y, Filipovich AH, Assa’ad AH et al (2008) Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol 121(6):1473–1483, 83 e1-4PubMedPubMedCentralCrossRef
103.
Haldar P, Brightling CE, Singapuri A, Hargadon B, Gupta S, Monteiro W et al (2014) Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol 133(3):921–923PubMedCrossRef
104.
Kim YJ, Prussin C, Martin B, Law MA, Haverty TP, Nutman TB et al (2004) Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J Allergy Clin Immunol 114(6):1449–1455PubMedCrossRef
105.
Koike M, Nakamura K, Furuya A, Iida A, Anazawa H, Takatsu K et al (2009) Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity. Hum Antibodies 18(1–2):17–27PubMed
106.
Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM et al (2010) MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 125(6):1344 e2–1353 e2PubMedCrossRef
107.
Wechsler ME, Fulkerson PC, Bochner BS, Gauvreau GM, Gleich GJ, Henkel T et al (2012) Novel targeted therapies for eosinophilic disorders. J Allergy Clin Immunol 130(3):563–571PubMedPubMedCentralCrossRef
108.
Busse WW, Katial R, Gossage D, Sari S, Wang B, Kolbeck R et al (2010) Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 125(6):1237 e2–1244 e2PubMedCrossRef
109.
110.
Chatila TA (2004) Interleukin-4 receptor signaling pathways in asthma pathogenesis. Trends Mol Med 10(10):493–499PubMedCrossRef
111.
Getz EB, Fisher DM, Fuller R (2009) Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma. J Clin Pharmacol 49:1025–1036CrossRef
112.
Wenzel SE, Ind PW, Otulana BA, Bleecker ER, Kuna P, Yen YP (2010) Inhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma. Eur Respir J Suppl 36:P3982
113.
Wenzel SE, Ind PW, Otulana BA, Bowden A, Puthukkerial S, Tomkinson A (2011) A phase 2b study of inhaled pitrakinra, an Il-4/Il-13 antagonist, successfully identified responder subpopulations of patient with uncontrolled asthma. Am J Respir Crit Care Med 183:A6179
114.
Slager RE, Otulana BA, Hawkins GA, Yen YP, Peters SP, Wenzel SE et al (2012) IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist. J Allergy Clin Immunol 130(2):516 e4–522 e4PubMedCrossRef
115.
Hershey GK (2003) IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 111(4):677–690, quiz 91PubMedCrossRef
116.
Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J et al (1999) Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 103(6):779–788PubMedPubMedCentralCrossRef
117.
Spahn JD, Szefler SJ, Surs W, Doherty DE, Nimmagadda SR, Leung DY (1996) A novel action of IL-13: induction of diminished monocyte glucocorticoid receptor-binding affinity. J Immunol 157(6):2654–2659PubMed
118.
Kraft M, Hamid Q, Chrousos GP, Martin RJ, Leung DY (2001) Decreased steroid responsiveness at night in nocturnal asthma. Is the macrophage responsible? Am J Respir Crit Care Med 163(5):1219–1225PubMedCrossRef
119.
Saha SK, Berry MA, Parker D, Siddiqui S, Morgan A, May R et al (2008) Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol 121(3):685–691PubMedPubMedCentralCrossRef
120.
Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD et al (2012) Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 130(3):647 e10–654 e10PubMedCrossRef
121.
Kanemitsu Y, Matsumoto H, Izuhara K, Tohda Y, Kita H, Horiguchi T et al (2013) Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol 132(2):305 e3–312 e3PubMedCrossRef
122.
Gotlib J (2014) World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. Am J Hematol 89(3):325–337PubMedCrossRef
123.
Klion AD, Bochner BS, Gleich GJ, Nutman TB, Rothenberg ME, Simon HU et al (2006) Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 117(6):1292–1302PubMedCrossRef
124.
Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE et al (2009) Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 124(6):1319 e3–1325 e3PubMedCrossRef
125.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031–1037PubMedCrossRef
126.
Schaller JL, Burkland GA (2001) Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Med Gen Med 3(5):9
127.
Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H (2002) Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 26(9):881–884PubMedCrossRef
128.
Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH (2002) Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359(9317):1577–1578PubMedCrossRef
129.
Pardanani A, Reeder T, Porrata LF, Li CY, Tazelaar HD, Baxter EJ et al (2003) Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 101(9):3391–3397PubMedCrossRef
130.
Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W et al (2003) Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 101(12):4714–4716PubMedCrossRef
131.
Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R (2003) Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A 100(13):7830–7835PubMedPubMedCentralCrossRef
132.
Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M et al (2004) Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103(2):473–478PubMedCrossRef
133.
Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S et al (2007) The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 92(9):1173–1179PubMedCrossRef
134.
Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G et al (2007) Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 109(11):4635–4640PubMedCrossRef
135.
Legrand F, Renneville A, Macintyre E, Mastrilli S, Ackermann F, Cayuela JM et al. (2013) The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia: new insights based on a survey of 44 cases. Medicine
136.
Pardanani A, D’Souza A, Knudson RA, Hanson CA, Ketterling RP, Tefferi A (2012) Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome. Leukemia 26(11):2439–2441PubMedCrossRef
137.
Helbig G, Stella-Holowiecka B, Majewski M, Calbecka M, Gajkowska J, Klimkiewicz R et al (2008) A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Br J Haematol 141(2):200–204PubMedCrossRef
138.
Klion AD, Robyn J, Maric I, Fu W, Schmid L, Lemery S et al (2007) Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood 110(10):3552–3556PubMedPubMedCentralCrossRef
139.
Hochhaus A, La Rosee P (2004) Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18(8):1321–1331PubMedCrossRef
140.
Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliott MA et al (2006) FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 30(8):965–970PubMedCrossRef
141.
142.
von Bubnoff N, Sandherr M, Schlimok G, Andreesen R, Peschel C, Duyster J (2005) Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 19(2):286–287CrossRef
143.
Ohnishi H, Kandabashi K, Maeda Y, Kawamura M, Watanabe T (2006) Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T6741 mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy. Br J Haematol 134(5):547–549PubMedCrossRef
144.
Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM et al (2003) CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102(9):3093–3096PubMedCrossRef
145.
Pitini V, Arrigo C, Azzarello D, La Gattuta G, Amata C, Righi M et al (2003) Serum concentration of cardiac troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood 102(9):3456–3457, author reply 7PubMedCrossRef
146.
Verstovsek S, Tefferi A, Kantarjian H, Manshouri T, Luthra R, Pardanani A et al (2009) Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res Off J Am Assoc Cancer Res 15(1):368–373CrossRef
147.
Schnabel A, Csernok E, Braun J, Gross WL (1999) Inflammatory cells and cellular activation in the lower respiratory tract in Churg-Strauss syndrome. Thorax 54(9):771–778PubMedPubMedCentralCrossRef
148.
Kahn JE, Grandpeix-Guyodo C, Marroun I, Catherinot E, Mellot F, Roufosse F et al (2010) Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol 125(1):267–270PubMedCrossRef
149.
Bachert C, Vignola AM, Gevaert P, Leynaert B, Van Cauwenberge P, Bousquet J (2004) Allergic rhinitis, rhinosinusitis, and asthma: one airway disease. Immunol Allergy Clin N Am 24(1):19–43CrossRef
150.
Bachert C, Gevaert P, Holtappels G, Johansson SG, van Cauwenberge P (2001) Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol 107(4):607–614PubMedCrossRef
151.
Fokkens W, Lund V, Mullol J (2007) European position paper on rhinosinusitis and nasal polyps 2007. Rhinol Suppl (20):1–136
152.
Van Zele T, Gevaert P, Watelet JB, Claeys G, Holtappels G, Claeys C et al (2004) Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis. J Allergy Clin Immunol 114(4):981–983PubMedCrossRef
153.
Bateman ND, Shahi A, Feeley KM, Woolford TJ (2005) Activated eosinophils in nasal polyps: a comparison of asthmatic and non-asthmatic patients. Clin Otolaryngol Off J ENT-UK Off J Neth Soc Otorhinolaryngol Cervicofac Surg 30(3):221–225
154.
Bachert C, Zhang N, Holtappels G, De Lobel L, van Cauwenberge P, Liu S et al (2010) Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. J Allergy Clin Immunol 126(5):962–968, 8 e1-6PubMedCrossRef
155.
Pinto JM, Mehta N, DiTineo M, Wang J, Baroody FM, Naclerio RM (2010) A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology 48(3):318–324PubMed
156.
Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA et al (2011) Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 128(1):3 e6–20 e6, quiz 1–2PubMedCrossRef
157.
Abonia JP, Rothenberg ME (2012) Eosinophilic esophagitis: rapidly advancing insights. Annu Rev Med 63:421–434PubMedCrossRef
158.
Jyonouchi S, Brown-Whitehorn TA, Spergel JM (2009) Association of eosinophilic gastrointestinal disorders with other atopic disorders. Immunol Allergy Clin N Am 29(1):85–97CrossRef
159.
Blanchard C, Wang N, Stringer KF, Mishra A, Fulkerson PC, Abonia JP et al (2006) Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest 116(2):536–547PubMedPubMedCentralCrossRef
160.
Blanchard C, Stucke EM, Rodriguez-Jimenez B, Burwinkel K, Collins MH, Ahrens A et al (2011) A striking local esophageal cytokine expression profile in eosinophilic esophagitis. J Allergy Clin Immunol 127(1):208–217, 17 e1-7PubMedPubMedCentralCrossRef
161.
Stein ML, Collins MH, Villanueva JM, Kushner JP, Putnam PE, Buckmeier BK et al (2006) Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 118(6):1312–1319PubMedCrossRef
162.
Pentiuk S, Putnam PE, Collins MH, Rothenberg ME (2009) Dissociation between symptoms and histological severity in pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 48(2):152–160PubMedPubMedCentralCrossRef
163.
Dohil R, Newbury R, Fox L, Bastian J, Aceves S (2010) Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology 139(2):418–429PubMedCrossRef
164.
Fulkerson PC, Fischetti CA, McBride ML, Hassman LM, Hogan SP, Rothenberg ME (2006) A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation. Proc Natl Acad Sci U S A 103(44):16418–16423PubMedPubMedCentralCrossRef
165.
Waddell A, Ahrens R, Steinbrecher K, Donovan B, Rothenberg ME, Munitz A et al (2011) Colonic eosinophilic inflammation in experimental colitis is mediated by Ly6C(high) CCR2(+) inflammatory monocyte/macrophage-derived CCL11. J Immunol 186(10):5993–6003PubMedPubMedCentralCrossRef
166.
Justice JP, Borchers MT, Crosby JR, Hines EM, Shen HH, Ochkur SI et al (2003) Ablation of eosinophils leads to a reduction of allergen-induced pulmonary pathology. Am J Physiol Lung Cell Mol Physiol 284(1):L169–L178PubMedCrossRef
167.
Komai M, Tanaka H, Nagao K, Ishizaki M, Kajiwara D, Miura T et al (2010) A novel CC-chemokine receptor 3 antagonist, Ki19003, inhibits airway eosinophilia and subepithelial/peribronchial fibrosis induced by repeated antigen challenge in mice. J Pharmacol Sci 112(2):203–213PubMedCrossRef
168.
Royer JF, Schratl P, Lorenz S, Kostenis E, Ulven T, Schuligoi R et al (2007) A novel antagonist of CRTH2 blocks eosinophil release from bone marrow, chemotaxis and respiratory burst. Allergy 62(12):1401–1409PubMedCrossRef
169.
Schratl P, Royer JF, Kostenis E, Ulven T, Sturm EM, Waldhoer M et al (2007) The role of the prostaglandin D2 receptor, DP, in eosinophil trafficking. J Immunol 179(7):4792–4799PubMedCrossRef
170.
Sugimoto H, Shichijo M, Iino T, Manabe Y, Watanabe A, Shimazaki M et al (2003) An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro. J Pharmacol Exp Ther 305(1):347–352PubMedCrossRef
171.
Schuligoi R, Sturm E, Luschnig P, Konya V, Philipose S, Sedej M et al (2010) CRTH2 and D-type prostanoid receptor antagonists as novel therapeutic agents for inflammatory diseases. Pharmacology 85(6):372–382PubMedCrossRef
172.
Barnes N, Pavord I, Chuchalin A, Bell J, Hunter M, Lewis T et al (2012) A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy J Br Soc Allergy Clin Immunol 42(1):38–48CrossRef
173.
Straumann A, Hoesli S, Bussmann C, Stuck M, Perkins M, Collins LP et al (2013) Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy 68(3):375–385PubMedCrossRef
174.
Nutku E, Aizawa H, Hudson SA, Bochner BS (2003) Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 101(12):5014–5020PubMedCrossRef
175.
Verjan Garcia N, Umemoto E, Saito Y, Yamasaki M, Hata E, Matozaki T et al (2011) SIRPalpha/CD172a regulates eosinophil homeostasis. J Immunol 187(5):2268–2277PubMedCrossRef
176.
Kiwamoto T, Kawasaki N, Paulson JC, Bochner BS (2012) Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther 135(3):327–336PubMedPubMedCentralCrossRef
177.
Zimmermann N, McBride ML, Yamada Y, Hudson SA, Jones C, Cromie KD et al (2008) Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils. Allergy 63(9):1156–1163PubMedPubMedCentralCrossRef
178.
Munitz A, Bachelet I, Levi-Schaffer F (2006) Reversal of airway inflammation and remodeling in asthma by a bispecific antibody fragment linking CCR3 to CD300a. J Allergy Clin Immunol 118(5):1082–1089PubMedCrossRef
179.
Casale TB, Stokes JR (2011) Future forms of immunotherapy. J Allergy Clin Immunol 127(1):8–15, quiz 6–7PubMedCrossRef
180.
Senti G, Johansen P, Haug S, Bull C, Gottschaller C, Muller P et al (2009) Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy J Br Soc Allergy Clin Immunol 39(4):562–570CrossRef
181.
Klimek L, Willers J, Hammann-Haenni A, Pfaar O, Stocker H, Mueller P et al (2011) Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy J Br Soc Allergy Clin Immunol 41(9):1305–1312CrossRef
Metadaten
Titel
Biological Modulators in Eosinophilic Diseases
verfasst von
Panida Sriaroon
Mark Ballow
Publikationsdatum
17.08.2014
Verlag
Springer US
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 2/2016
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-014-8444-9

Weitere Artikel der Ausgabe 2/2016

Clinical Reviews in Allergy & Immunology 2/2016 Zur Ausgabe

ReviewPaper

Medical Complications of Tattoos: A Comprehensive Review

ReviewPaper

Eosinophilic Esophagitis: A Comprehensive Review

ReviewPaper

The Role and Immunobiology of Eosinophils in the Respiratory System: a Comprehensive Review

OriginalPaper

Eosinophilic Drug Allergy

ReviewPaper

The Eosinophil in Infection

ReviewPaper

Hypereosinophilic Syndrome

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

HNO-Op. auch mit über 90?

16.04.2024 | Tonsillektomie | Nachrichten

Intrakapsuläre Tonsillektomie gewinnt an Boden

15.04.2024 | Hörsturz | Nachrichten

Bilateraler Hörsturz hat eine schlechte Prognose

13.04.2024 | Klinik aktuell | Kongressbericht | Nachrichten

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“
weitere anzeigen

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen